Insider Transactions in Q2 2021 at Replimune Group, Inc. (REPL)
Insider Transaction List (Q2 2021)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 29
2021
|
Robert Coffin Director |
SELL
Open market or private sale
|
Direct |
22,826
-1.26%
|
$913,040
$40.05 P/Share
|
Jun 28
2021
|
Robert Coffin Director |
SELL
Open market or private sale
|
Direct |
14,663
-0.81%
|
$586,520
$40.04 P/Share
|
Jun 15
2021
|
Colin Love Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,000
-1.69%
|
$1,020,000
$34.16 P/Share
|
May 10
2021
|
Tanya Lewis Chief Dev. Op. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,333
+50.0%
|
-
|
May 03
2021
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,333
+50.0%
|
-
|
Apr 15
2021
|
Colin Love Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,000
-1.62%
|
$900,000
$30.34 P/Share
|
Apr 01
2021
|
Colin Love Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,285
+4.07%
|
-
|
Apr 01
2021
|
Philip Astley Sparke Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
85,415
+5.99%
|
-
|
Apr 01
2021
|
Robert Coffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
76,865
+4.05%
|
-
|
Apr 01
2021
|
Jean M. Franchi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,035
+50.0%
|
-
|
Apr 01
2021
|
Andrea Pirzkall Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+48.81%
|
-
|
Apr 01
2021
|
Pamela Esposito Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,165
+13.98%
|
-
|